Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Cardiology
|
| gptkbp:administered_by |
gptkb:Nurse
gptkb:pharmaceuticals gptkb:Cardiology Healthcare professional |
| gptkbp:affects |
Contractility
Heart rate |
| gptkbp:approves |
1950s
|
| gptkbp:atccode |
C01 AA05
|
| gptkbp:available_on |
Injection
Oral tablet |
| gptkbp:brand |
gptkb:Lanoxin
Digitek |
| gptkbp:can_cause |
Digoxin toxicity
|
| gptkbp:casnumber |
20830-75-5
|
| gptkbp:chemical_formula |
C41 H64 O14
|
| gptkbp:contraindication |
Ventricular fibrillation
Hypersensitivity to digoxin |
| gptkbp:developed_by |
Foxglove plant
|
| gptkbp:discovered_by |
gptkb:19th_century
|
| gptkbp:excretion |
Kidneys
|
| https://www.w3.org/2000/01/rdf-schema#label |
Digoxin
|
| gptkbp:interacts_with |
gptkb:Amiodarone
gptkb:Quinidine gptkb:Verapamil Diuretics |
| gptkbp:is_considered |
Essential medicine by WHO
|
| gptkbp:is_monitored_by |
Electrolytes
Serum levels |
| gptkbp:is_part_of |
Cardiac treatment regimen
|
| gptkbp:is_subject_to |
Clinical guidelines
Drug interactions Regulatory approval Dosage adjustments Prescription requirements |
| gptkbp:is_used_in |
gptkb:hospice_care
Pediatric cardiology Geriatric medicine |
| gptkbp:mass |
780.94 g/mol
|
| gptkbp:mechanism_of_action |
Inhibits Na+/ K+ ATPase
|
| gptkbp:metabolism |
Liver
|
| gptkbp:side_effect |
gptkb:Nausea
Dizziness Vomiting Visual disturbances |
| gptkbp:suitable_for |
Pregnant women
Patients with electrolyte imbalances Patients with renal impairment Patients with thyroid disorders |
| gptkbp:symptoms |
Bradycardia
Arrhythmias Digoxin toxicity |
| gptkbp:treatment |
Atrial flutter
Heart failure with reduced ejection fraction |
| gptkbp:used_for |
Heart failure
Atrial fibrillation |
| gptkbp:bfsParent |
gptkb:Lansoprazole
gptkb:Propranolol |
| gptkbp:bfsLayer |
6
|